Therapeutic progression of recurrent nasopharyngeal carcinoma

Abstract

Ma Xuan, Li Xiaojiang. Therapeutic progression of recurrent nasopharyngeal carcinoma[J]. Journal of International Oncology, 2015, 42(2): 134-137.

［1］ Xu T, Tang J, Gu M, et al. Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge［J］. Curr Oncol, 2013, 20(5): 406-419. ［2］卢泰祥, 韩非, 李嘉欣. 复发鼻咽癌临床研究进展［J］. 中国癌症杂志, 2008, 18(9): 661-666. ［3］钟毓, 黎静. 复发鼻咽癌的治疗研究进展［J］. 医疗卫生装备, 2009, 30（7）: 37-40. ［4］韩非, 卢泰祥. 复发鼻咽癌的挽救治疗［J］. 肿瘤学杂志, 2009, 15(7): 606-608. ［5］陈俊妮, 陈显钊, 林少民. 鼻咽癌常规放疗存在的若干问题探讨［J］. 海南医学, 2011, 22(6): 116-118. ［6］ Suárez C, Rodrigo JP, Rinaldo A, et al. Current treatment options for recurrent nasopharyngeal cancer［J］. Eur Arch Otorhinolaryngol, 2010, 267(12): 1811-1824. ［7］ Leung TW, Wong VY, Tung SY. Stereotactic radiotherapy for locally recurrent nasopharyngeal carcinoma［J］. Int J Radiat Oncol Biol Phys, 2009, 75(3): 734-741. ［8］ Seo Y, Yoo H, Yoo S, et al. Robotic systembased fractionated stereotactic radiotherapy in locally recurrent nasopharyngeal carcinoma［J］. Radiother Oncol, 2009, 93(3): 570-574. ［9］ Zhang F, Wu K, Gao F, et al. Refractory nasopharyngeal carcinoma: positron emission tomography combined with computed tomographyguided 125I seed implantation therapy after repeated traditional radiochemotherapy［J］. Otolaryngol Head Neck Surg, 2013, 149(3): 417-423. ［10］ Cheah SK, Lau FN, Yusof MM, et al. Treatment outcome with brachytherapy for recurrent nasopharyngeal carcinoma［J］. Asian Pac J Cancer Prev, 2013, 14(11): 6513-6518. ［11］ Rosenblatt E, AbdelWahab M, ElGantiry M, et al. Brachytherapy boost in locoregionally advanced nasopharyngeal carcinoma: a prospective randomized trial of the International Atomic Energy Agency［J］. Radiat Oncol, 2014, 9: 67. ［12］邱素芳, 林少俊, 陆军, 等. 140例局部复发鼻咽癌患者三维适形放疗的疗效分析［J］. 中国癌症杂志, 2011, 21(9): 701-707. ［13］ Hua YJ, Han F, Lu LX, et al. Longterm treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy［J］. Eur J Cancer, 2012, 48(18): 3422-3428. ［14］张小红, 张海霞, 余伟, 等. 鼻咽癌调强放疗与适形放疗的疗效和副反应比较研究［J］. 贵州医药, 2014, 38(2): 109-112. ［15］ Chua DT, Sham JS, Au GK. Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma［J］. Am J Clin Oncol, 2005, 28(5): 464-471. ［16］高健全, 高天生, 董智荣, 等. 诱导化疗加同期放化疗治疗T34N23M0 期鼻咽癌的前瞻性随机对照研究［J］. 肿瘤学杂志, 2013, 19(3): 161-165. ［17］ Poon D, Yap SP, Wong ZW, et al. Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma［J］. Int J Radiat Oncol Biol Phys, 2004, 59(5): 1312-1318. ［18］ Lin JC, Jan JS, Hsu CY, et al. Phase Ⅲ study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progressionfree survival［J］.J Clin Oncol, 2003, 21(4): 631-637. ［19］ Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrentadjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma［J］. J Natl Cancer Inst, 2010, 102(15): 1188-1198. ［20］ Chi KH, Chang YC, Guo WY, et al. A phase Ⅲ study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients［J］. Int J Radiat Oncol Biol Phys, 2002, 52(5): 1238-1244. ［21］ Chen C, Wang FH, An X, et al. Triplet combination with paclitaxel, cisplatin and 5FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma［J］. Cancer Chemother Pharmacol, 2013, 71(2): 371-378. ［22］吴宇. 不同外科手术方式在鼻咽癌放疗后颈淋巴结残留或复发补救治疗中的应用研究［D］. 福建: 福建医科大学, 2012. ［23］ Tsang RK, To VS, Ho AC, et al. Early results of robotic assisted nasopharyngectomy for recurrent nasopharyngeal carcinoma［J］. Head Neck, 2014, In press. ［24］赵礼君, 朱雪琪. 鼻内镜下手术治疗鼻咽癌局部复发病灶 23例［J］. 浙江中西医结合杂志, 2013, 23(12): 1016-1018. ［25］蒋骑, 黄俊辉, 胡冰, 等. 重组人血管内皮抑制素联合化疗治疗晚期鼻咽癌的疗效观察［J］. 中国耳鼻咽喉颅底外科杂志, 2013, 19(4): 365-367. ［26］ Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multiinstitutional trial［J］. Lancet Oncol, 2012, 13(2): 172-180.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[4]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[5]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[6]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[7]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[8]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[9]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[10]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[11]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[12]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[13]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[14]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[15]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.

Therapeutic progression of recurrent nasopharyngeal carcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments